Proteomic signatures associated with p53 mutational status in lung adenocarcinoma

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

(2014) Patricia A.J. Muller et al.   CANCER CELL

Antitumor effect of miR-197 targeting in p53 wild-type lung cancer

(2014) M E Fiori et al.   CELL DEATH AND DIFFERENTIATION

Blood/plasma secretome and microvesicles

(2013) Jameel M. Inal et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL

(2013) A Meijer et al.   BRITISH JOURNAL OF CANCER

PGC1α Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress

(2013) Francisca Vazquez et al.   CANCER CELL

CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer

(2013) Kit W. Tam et al.   Journal of Thoracic Oncology

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

p53 Orchestrates the PGC-1α-Mediated Antioxidant Response Upon Mild Redox and Metabolic Imbalance

(2012) Katia Aquilano et al.   ANTIOXIDANTS & REDOX SIGNALING

PGC-1  Promotes the Growth of ErbB2/Neu-Induced Mammary Tumors by Regulating Nutrient Supply

(2012) E. Klimcakova et al.   CANCER RESEARCH

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

(2012) Marcin Imielinski et al.   CELL

ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour

(2012) Badreddin Edris et al.   JOURNAL OF PATHOLOGY

p53 mutations in cancer

(2012) Patricia A. J. Muller et al.   NATURE CELL BIOLOGY

Mutant p53 drives invasion in breast tumors through up-regulation of miR-155

(2012) P M Neilsen et al.   ONCOGENE

The diverse role of the PPARγ coactivator 1 family of transcriptional coactivators in cancer

(2012) Geoffrey D. Girnun   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Lung Cancer Signatures in Plasma Based on Proteome Profiling of Mouse Tumor Models

(2011) Ayumu Taguchi et al.   CANCER CELL

PGC1  Promotes Tumor Growth by Inducing Gene Expression Programs Supporting Lipogenesis

(2011) K. Bhalla et al.   CANCER RESEARCH

Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways

(2011) Olorunseun O. Ogunwobi et al.   CLINICAL & EXPERIMENTAL METASTASIS

Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-mediated epithelial-mesenchymal transition

(2011) Dayong Ren et al.   GENES TO CELLS

PGC-1α, a Key Modulator of p53, Promotes Cell Survival upon Metabolic Stress

(2011) Nirmalya Sen et al.   MOLECULAR CELL

Telomere dysfunction induces metabolic and mitochondrial compromise

(2011) Ergün Sahin et al.   NATURE

Peroxisome proliferator-activated receptor-  coactivator 1-  (PGC1 ) is a metabolic regulator of intestinal epithelial cell fate

(2011) I. D'Errico et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise

(2011) A. Mandinova et al.   Science Translational Medicine

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors

(2010) Matthew H. Kulke et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)

(2010) Michael R. Harrison et al.   INVESTIGATIONAL NEW DRUGS

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer

(2010) Qing Zhou et al.   INVESTIGATIONAL NEW DRUGS

Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase

(2010) H Yamamoto et al.   ONCOGENE

Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity

(2010) F. Weinberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma

(2009) Kazuhito Morioka et al.   CANCER SCIENCE

Blinded by the Light: The Growing Complexity of p53

(2009) Karen H. Vousden et al.   CELL

Epithelial-Mesenchymal Transitions in Development and Disease

(2009) Jean Paul Thiery et al.   CELL

The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma

(2009) M P O’Connell et al.   ONCOGENE

Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2

(2008) Changgong Li et al.   BMC MOLECULAR BIOLOGY

The dark side of a tumor suppressor: anti-apoptotic p53

(2008) R U Jänicke et al.   CELL DEATH AND DIFFERENTIATION

Proteomic Analysis of Ovarian Cancer Cells Reveals Dynamic Processes of Protein Secretion and Shedding of Extra-Cellular Domains

(2008) Vitor M. Faça et al.   PLoS One